Close Menu

NEW YORK (GenomeWeb) – Investment bank Janney upgraded Foundational Medicine to Neutral from Sell today, citing a recent rebound in the company's shares which analyst Paul Knight attributed to an expected easy sequential earnings comparison for the company in the first quarter, among other reasons.

Earlier this month, Foundation Medicine announced that it had received the first payment from Palmetto GBA — its Medicare Administrative Contractor in North Carolina — for the Foundation One genomic profiling assay for Stage IIIB/IV non-small cell lung cancer.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
26

As new variants of SARS-CoV-2 circulate around the globe, there is growing concern among clinical laboratories that these variants may impact their ability to accurately detect the virus.